NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History.

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals.

6 brokerages have issued 12-month target prices for Galmed Pharmaceuticals' stock. Their forecasts range from $10.00 to $28.00. On average, they expect Galmed Pharmaceuticals' share price to reach $19.00 in the next year. This suggests a possible upside of 207.9% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

News stories about GLMD stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Galmed Pharmaceuticals.

Some companies that are related to Galmed Pharmaceuticals include Morphic (MORF), Neoleukin Therapeutics (NLTX), Milestone Pharmaceuticals (MIST), Viking Therapeutics (VKTX), CytoDyn (CYDY), Prothena (PRTA), BioDelivery Sciences International (BDSI), Satsuma Pharmaceuticals (STSA), BioSpecifics Technologies (BSTC), Organogenesis (ORGO), Sinovac Biotech (SVA), Cue Biopharma (CUE), Beyondspring (BYSI), ProQR Therapeutics (PRQR) and Merus (MRUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Rite Aid (RAD), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Immunomedics (IMMU), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), SCYNEXIS (SCYX) and Verastem (VSTM).

Galmed Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.92%), Voss Capital LLC (0.72%), P.A.W. Capital Corp (0.48%), ARK Investment Management LLC (0.43%), Renaissance Technologies LLC (0.31%) and Phoenix Holdings Ltd. (0.09%).

GLMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd..

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Voss Capital LLC, Raymond James & Associates, Renaissance Technologies LLC, P.A.W. Capital Corp, ARK Investment Management LLC and Tower Research Capital LLC TRC .

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLMD stock can currently be purchased for approximately $6.17.

Galmed Pharmaceuticals has a market capitalization of $129.69 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.

The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/.

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.